Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase EARLY_PHASE1 1

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Conditions

Leukemia, Myeloid, Acute 69Multiple Myeloma 44Precursor Cell Lymphoblastic Leukemia-Lymphoma 42Myelodysplastic Syndromes 37Lymphoma 37Leukemia, Lymphocytic, Chronic, B-Cell 37Lymphoma, Non-Hodgkin 33Leukemia 32Recurrence 31Lymphoma, B-Cell 30Melanoma 27Lymphoma, Large B-Cell, Diffuse 22Ovarian Neoplasms 17Lymphoma, Mantle-Cell 17Lymphoma, Follicular 16Hematologic Neoplasms 16Carcinoma, Non-Small-Cell Lung 16Burkitt Lymphoma 16Neoplasms 15Lymphoma, B-Cell, Marginal Zone 13Hodgkin Disease 13Carcinoma, Renal Cell 12Head and Neck Neoplasms 11Neuroblastoma 10Leukemia, Biphenotypic, Acute 10Graft vs Host Disease 10Neoplasms, Plasma Cell 9Neoplasm Metastasis 9Colorectal Neoplasms 9Breast Neoplasms 9

Interventions

fludarabine 2Cyclophosphamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Autoimmune Diseases of the Nervous System × fludarabine × Clear all
NCT07526493 2026-05-12

Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.

Tongji Hospital

Phase 1 Recruiting
6 enrolled

Multiple Sclerosis, Myasthenia Gravis, Myositis, Neuromyelitis Optica, Autoimmune Diseases of the Nervous System, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

NCT06626919 2026-02-25

A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases

Arcellx, Inc.

Phase 1 Recruiting
30 enrolled

Autoimmune Diseases, Muscular Diseases, Myasthenia Gravis, Muscle Weakness, Autoimmune Diseases of the Nervous System, Neuromuscular Manifestations

Data powered by HemOnc (CC BY 4.0) Colophon âš¡